A passion for learning took her from apartheid South Africa to a beer brewery to becoming a healthcare consultant, all before ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

Mass firings at the FDA have decimated divisions tasked with releasing public records generated by the agency's regulatory ...

PFE stock is likely to be a great pick for value investors, considering its cheap valuation, as well as for income investors ...

Officials say the Army has reenlisted more than 23 soldiers who were discharged for refusing the COVID-19 vaccine.

British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay.

Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...

In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field: Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA). If Pfizer and Moderna can ...

Novavax uses protein-based technology, a more traditional method than the mRNA vaccines from Pfizer and Moderna ... showed our vaccine is safe and effective for the prevention of COVID-19.” “We are ...